Newsroom

Please follow us on LinkedIn if you’d like to stay up-to-date with our latest news.

Press releases

Abstract Accepted for Oral Presentation at EANM on DETECT Study Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

London, UK, 9 July 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been accepted for oral presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany.

Expanded Access to Medicine Policy

Adopted by the Company on 09 July 2024

Serac Healthcare is dedicated to developing maraciclatide as a new molecular imaging agent that will have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.

⁹⁹ᵐTc-Maraciclatide Granted FDA Fast Track Designation for the Diagnosis of Superficial Peritoneal Endometriosis

London, UK, 2 July 2024. Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to 99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualisation and diagnosis of superficial peritoneal endometriosis in women of 16 years and older.

Continuing Positive Results for Imaging of Endometriosis with ⁹⁹ᵐTc-Maraciclatide

London, UK, 7 June 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that further
data has been presented from the “Detecting Endometriosis expressed integrins using technetium99m” (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data is being presented in a poster today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, at the 7th European Endometriosis Congress taking place from 6-8 June 2024 in Bucharest, Romania.

Imaging with ⁹⁹ᵐTc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

London, UK, 15 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study, indicating that ⁹⁹ᵐTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data was presented today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, in an oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

⁹⁹ᵐTc-Maraciclatide Phase I Data Published in Nuclear Medicine Communications

London, UK, 14 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ⁹⁹ᵐTc-maraciclatide, announces the publication of Phase I data demonstrating the safety, biodistribution and radiation dosimetry of ⁹⁹ᵐTc-maraciclatide in the April 2024 edition of Nuclear Medicine Communications.

Events

Updates on our clinical programmes will be presented at upcoming conferences including: